Quarterly report pursuant to Section 13 or 15(d)

Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail)

v3.20.1
Research and Development Agreements - Schedule of Deferred Revenue, Other Liabilities for Co-share Payments and Accounts Receivable Balances from the Research and Development Agreements (Detail) - USD ($)
$ in Thousands
Mar. 31, 2020
Dec. 31, 2019
Assets    
Accounts receivable $ 1,300 $ 408
Liabilities    
Other current liabilities 2,543 2,501
Other liabilities 3,143 1,366
Total liabilities 76,977 71,174
Takeda Pharmaceuticals Inc    
Assets    
Accounts receivable 1,300 408
Liabilities    
Other current liabilities 7,754 0
Deferred revenue, current 8,773 8,780
Deferred revenue, non-current 1,355 441
Other liabilities 1,746 0
Total liabilities $ 19,628 $ 9,221